Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?

Παρόμοια τεκμήρια

• Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
  ανά: Tonkin, A, κ.ά.
  Έκδοση: (2006)
• Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
  ανά: Colquhoun, D, κ.ά.
  Έκδοση: (2004)
• Pravastatin therapy and the risk of stroke.
  ανά: White, H, κ.ά.
  Έκδοση: (2000)
• Detection of 4a,5-dihydropravastatin as Impurity in the Cholesterol Lowering Drug Pravastatin
  ανά: Wibo B. van Scheppingen, κ.ά.
  Έκδοση: (2021-08-01)
• Monitoring cholesterol levels: measurement error or true change?
  ανά: Glasziou, P, κ.ά.
  Έκδοση: (2008)